CLL-1 Targeting Antibodies for Hematologic Malignancy Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for hematologic malignancies, such as those targeting CD33, often result in severe side effects due to cross-reactivity with normal cells, highlighting the need for therapies that specifically target CLL-1, a cell surface glycoprotein predominantly expressed on myeloid cells, to minimize adverse effects.
Innovation Solution
Development of isolated antibodies or antibody fragments with high affinity for CLL-1 epitopes, including chimeric, humanized, or human antibodies, which can be used to diagnose and treat hematologic malignancies by binding specifically to CLL-1, thereby reducing side effects associated with existing therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies targeting CD33 are used to treat hematologic malignancies, then cancer cells can be targeted, but severe side effects occur due to cross-reactivity with normal cells
Solution Approach 1:
The patent applies local quality by developing antibodies that specifically recognize CLL-1, a glycoprotein selectively expressed on myeloid cells and their derivatives. This localized targeting approach ensures that the therapeutic effect is concentrated on the intended cancer cells while minimizing off-target effects on normal tissues, thereby resolving the contradiction between treatment efficacy and side effect reduction.
2Object-affected harmful factors
If tumor-specific antigens are targeted to reduce cross-reactivity, then side effects are minimized, but identification of such antigens is challenging
Solution Approach 1:
The patent employs an intermediary approach by using CLL-1 as a marker protein that mediates the identification and targeting of myeloid malignancies. CLL-1 serves as a bridge between the immune system and the cancer cells, providing a specific target that is both tumor-associated and distinguishable from normal tissues, thus facilitating effective therapy with minimal cross-reactivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies or antibody fragments effectively target CLL-1-expressing cells, potentially offering a more specific and less toxic treatment option for hematologic malignancies by minimizing cross-reactivity with normal tissues, thereby reducing severe side effects.
Implementation Method 1
Development of isolated antibodies or antibody fragments with high affinity for CLL-1 epitopes
Data Source
AI summary
Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1.